Phase 3 Readout
SLS: Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth
December 1, 2026 · galinpepimut-s. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2026
- Company
- SELLAS Life Sciences Group, Inc. (SLS)
- Drug
- galinpepimut-s
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth
- Drug
- galinpepimut-s
- Indication
- Acute Myeloid Leukemia